Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease

NCT00199433 is registered in ClinicalTrials.gov with Kyowa Kirin, Inc. as lead sponsor.

NCT NCT00199433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00199433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of 40mg/Day KW-6002 (Istradefylline) as Monotherapy in Subjects With Parkinson's Disease
Lead sponsor
Kyowa Kirin, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2005
Completion date
August 31, 2006
Enrollment
160
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

movement disorder syndrome, parkinson's disease